Janneke Meulenberg, Ph.D.

Janneke Meulenberg has 20+ years of experience in leadership positions in the Biopharmaceutical industry. Prior to joining ORCA, she was a management team member of Amsterdam Molecular Therapeutics  (AMT: now UniQure). She was responsible for successful development of AMT’s lead product Glybera® , the first gene therapy to receive market approval in the Western World. At ID-Lelystad, Janneke headed a world leading R&D team to develop veterinary vaccines in collaboration with Boehringer Ingelheim. She graduated cum laude, received a PhD in Biochemistry and holds an MBA from RSM Erasmus University. She is author of numerous peer-reviewed publications and book chapters, and inventor on several patents.

Ramon Alemany, Ph.D.

Ramon Alemany is laboratory director in the Catalan Institute of Oncology (ICO), Barcelona, Spain. He has held various research positions at MD Anderson Cancer Center, Baxter Healthcare (Round Lake, IL) and the University of Alabama. He is author of more than 50 original publications in the field of gene therapy and virotherapy with adenoviruses, patents, reviews and book chapters and is reviewer for different journals and (inter)national granting agencies. He has been member of the Executive Board of Spanish Society of Gene and Cell Therapy, consultant of companies involved in adenovirus vector development, and he is on the Scientific Advisory Board of Oncolytics Biotech Inc. and chairman of the scientific committee of VCN Biosciences.

Professor Winald Gerritsen, MD, Ph.D.

Winald Gerritsen is a medical oncologist and professor in tumor Immunology at the Radboud University Nijmegen Medical Centre. He has a strong background in translational research. Following his medical training at the University of Nijmegen, Prof. Gerritsen achieved his PhD in 1989 on bone marrow transplantation at the Medical School of the Erasmus University of Rotterdam. From 1989 till 1991 he worked as a special fellow at Memorial Sloan Kettering Cancer Center in New York, after which he held several positions at respectively the University Hospital Utrecht, The Netherlands Cancer Institute / Antoni van Leeuwenhoek Hospital and the VU University Medical Center, where he was Director of the VUmc Cancer Center Amsterdam. As principal investigator, he has been involved in a variety of (clinical) studies with immunotherapeutic compounds.